NASDAQ:EPIX

ESSA Pharma - EPIX Stock Forecast, Price & News

$3.32

-0.15 (-4.32%)

(As of 12/6/2022 12:00 AM ET)

Add

Compare

Today's Range: $3.23
▼
$3.44
50-Day Range: $1.50
▼
$4.82
52-Week Range: $1.40
▼
$14.88

Volume: 91,586 shs
Average Volume: 1.12 million shs
Market Capitalization: $146.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.00

ESSA Pharma MarketRank™ Forecast

Analyst Rating: N/A
0.00 Rating Score
Upside/Downside: 502.4% Upside
$20.00 Price Target
Short Interest: Healthy
3.34% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$5.97 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.94) to ($1.16) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

801st out of 1,023 stocks

Pharmaceutical Preparations Industry

395th out of 501 stocks

2.0

Analyst's Opinion

Price Target Upside/Downside
According to analysts' consensus price target of $20.00, ESSA Pharma has a forecasted upside of 502.4% from its current price of $3.32.
Amount of Analyst Coverage
ESSA Pharma has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
3.34% of the float of ESSA Pharma has been sold short.
Short Interest Ratio / Days to Cover
ESSA Pharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ESSA Pharma has recently decreased by 69.39%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
ESSA Pharma does not currently pay a dividend.
Dividend Growth
ESSA Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EPIX.

2.0

News and Social Media Coverage

News Sentiment
ESSA Pharma has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for ESSA Pharma this week, compared to 1 article on an average week.
Search Interest
Only 13 people have searched for EPIX on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added ESSA Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ESSA Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,970,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 9.90% of the stock of ESSA Pharma is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for ESSA Pharma are expected to decrease in the coming year, from ($0.94) to ($1.16) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ESSA Pharma is -3.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ESSA Pharma is -3.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ESSA Pharma has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ESSA Pharma (NASDAQ:EPIX) Stock

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Receive EPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.

EPIX Stock News Headlines

November 15, 2022 | finance.yahoo.com

EPIX: Promising Early Data for EPI-7386 in Combination with Enzalutamide…

November 10, 2022 | finance.yahoo.com

ESSA Pharma to Participate in Two Upcoming Investor Conferences

October 31, 2022 | finance.yahoo.com

J&J suspends enrollment in clinical trial assessing Essa Pharma's prostate cancer treatment

October 31, 2022 | finance.yahoo.com

ESSA Pharma Shares Tank As Janssen Stops Enrollment In EPI-7386 Combo Prostate Cancer Trials

October 26, 2022 | barrons.com

(PR) ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium

October 26, 2022 | finance.yahoo.com

Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat

September 21, 2022 | finance.yahoo.com

ESSA Pharma Appoints Philip Kantoff to its Board of Directors

September 6, 2022 | reuters.com

ESSA Pharma Inc

August 25, 2022 | seekingalpha.com

ESSA Pharma Inc.: Selling For Under Cash Value

August 16, 2022 | benzinga.com

Multiple Ongoing Studies of EPI-7386

August 4, 2022 | finance.yahoo.com

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022

July 21, 2022 | nasdaq.com

EPIX Stock Gains 11.6% on Insider Buys

July 11, 2022 | finance.yahoo.com

EPIX: Encouraging Signs of Activity in Phase 1 Trial of EPI-7386…

June 30, 2022 | finance.yahoo.com

ESSA Pharma Insiders Establish Automatic Securities Disposition Plans

June 27, 2022 | finance.yahoo.com

ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development

June 2, 2022 | finance.yahoo.com

ESSA Pharma to Present at 2022 Jefferies Healthcare Conference

May 27, 2022 | finance.yahoo.com

EPIX: Clinical Update on Phase 1 Monotherapy Trial of EPI-7386 Expected in 2Q22…

May 10, 2022 | finance.yahoo.com

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022

April 26, 2022 | finance.yahoo.com

ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

April 25, 2022 | finance.yahoo.com

EPIX: Preclinical Data on Androgen Receptor N-Terminal Domain Degrader Presented at AACR…

April 8, 2022 | finance.yahoo.com

ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders

March 10, 2022 | finance.yahoo.com

ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference

March 8, 2022 | finance.yahoo.com

ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting

March 6, 2022 | fool.com

ESSA Pharma Inc.(EPIX)

February 4, 2022 | finance.yahoo.com

EPIX: First Patient Dosed in Combination Trial of EPI-7386 and Enzalutamide…

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive EPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.

EPIX Company Calendar

Last Earnings: 11/18/2021
Today: 12/06/2022
Next Earnings (Estimated): 2/01/2023
Fiscal Year End: 9/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:EPIX
CUSIP: N/A
CIK: 1633932
Web: www.essapharma.com
Phone: 778-331-0962
Fax: 604-738-4080
Employees: 25
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $20.00
High Stock Price Forecast: $20.00
Low Stock Price Forecast: $20.00
Forecasted Upside/Downside: +502.4%
Consensus Rating: N/A
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.86)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-36,810,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -20.39%
Return on Assets: -19.95%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 43.43
Quick Ratio: 43.43

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.41 per share
Price / Book: 0.75

Miscellaneous

Outstanding Shares: 44,073,000
Free Float: 39,710,000
Market Cap: $146.32 million
Optionable: Not Optionable
Beta: 2.04

Key Executives

Dr. David Ross Parkinson M.D. (Age 72)
Pres, CEO & Director
Comp: $829.56k

Mr. David S. Wood C.M.A. (Age 65)
CPA, M.B.A., MBA, CPA, CMA, Chief Financial Officer
Comp: $532.35k

Mr. Peter A. Virsik M.B.A. (Age 51)
M.S., Exec. VP & COO
Comp: $646.75k

Dr. Alessandra Cesano M.D. (Age 62)
Ph.D., Chief Medical Officer
Comp: $620.81k

Chandtip Chandhasin
Exec.

Erica Osbourne
Exec.

Erin Rudsinski
Exec.

Loleta Harris
Exec.

Neil Thapar
Exec.

Nkengyal Barber
Exec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EPIX Stock - Frequently Asked Questions

What is ESSA Pharma's stock price forecast for 2023?: 0 Wall Street analysts have issued 12-month price objectives for ESSA Pharma's shares. Their EPIX share price forecasts range from $20.00 to $20.00. On average, they expect the company's stock price to reach $20.00 in the next year. This suggests a possible upside of 502.4% from the stock's current price.
View analysts price targets for EPIX or view top-rated stocks among Wall Street analysts.
How have EPIX shares performed in 2022?: ESSA Pharma's stock was trading at $14.20 at the beginning of the year. Since then, EPIX stock has decreased by 76.6% and is now trading at $3.32.
View the best growth stocks for 2022 here.
Are investors shorting ESSA Pharma?: ESSA Pharma saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 618,300 shares, a decline of 69.4% from the October 31st total of 2,020,000 shares. Based on an average daily volume of 3,200,000 shares, the short-interest ratio is presently 0.2 days. Approximately 3.3% of the shares of the company are sold short.
View ESSA Pharma's Short Interest.
When is ESSA Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 1st 2023.
View our EPIX earnings forecast.
How were ESSA Pharma's earnings last quarter?: ESSA Pharma Inc. (NASDAQ:EPIX) posted its quarterly earnings data on Thursday, November, 18th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.03.

What other stocks do shareholders of ESSA Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include RedHill Biopharma (RDHL), Aurinia Pharmaceuticals (AUPH), Lipocine (LPCN), Trevena (TRVN), Allena Pharmaceuticals (ALNA), Protalix BioTherapeutics (PLX), Agile Therapeutics (AGRX), Biopharmx (BPMX), Corbus Pharmaceuticals (CRBP) and Heat Biologics (HTBX).
What is ESSA Pharma's stock symbol?: ESSA Pharma trades on the NASDAQ under the ticker symbol "EPIX."
Who are ESSA Pharma's major shareholders?: ESSA Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include BVF Inc. IL (19.85%), Bellevue Group AG (13.38%), Eventide Asset Management LLC (3.54%), PFM Health Sciences LP (3.35%), RTW Investments LP (2.98%) and Bioimpact Capital LLC (0.92%). Insiders that own company stock include David Ross Parkinson, Franklin M Berger and Growth N V Biotech.
View institutional ownership trends.
How do I buy shares of ESSA Pharma?: Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ESSA Pharma's stock price today?: One share of EPIX stock can currently be purchased for approximately $3.32.
How much money does ESSA Pharma make?: ESSA Pharma (NASDAQ:EPIX) has a market capitalization of $146.32 million. The company earns $-36,810,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis.
How can I contact ESSA Pharma?: ESSA Pharma's mailing address is 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5. The official website for the company is www.essapharma.com. The company can be reached via phone at 778-331-0962, via email at alada@troutgroup.com, or via fax at 604-738-4080.

This page (NASDAQ:EPIX) was last updated on 12/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial